Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AMP945
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Recipient : Amplia Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Amplia Receives Grant to Collaborate with CSIRO – Supplementary Announcement
Details : The research collaboration with CSIRO will help to develop formulations of its small molecule FAK inhibitors, including AMP945 that could be applied topically to wounds and burns to aid healing and reduce scarring.
Brand Name : AMP945
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 23, 2023
Lead Product(s) : AMP945
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Recipient : Amplia Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Recce 327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Recce Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : RECCE® 327 and New RECCE® 529 compounds were selected for their unique mechanisms of action against hyper-mutation, as indicated on bacteria and viruses (respectively).
Brand Name : Recce 327
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 08, 2020
Lead Product(s) : Recce 327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Recce Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
